Notably, ICIs targeting PD‐1 (programmed cell death protein 1), PD‐L1 (programmed death‐ligand 1), and CTLA‐4 (cytotoxic T‐lymphocyte‐associated protein 4) in conjunction with personalized cancer vaccines has shown promising results. This evidence concerns the gene CTLA4 and cancer.